CANCER CHEMOTHERAPY ASSOCIATED NAUSEA AND VOMITING THERAPEUTICS MARKET ANALYSIS

Market News

Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- Key Developments

In May 2021, Tetra Bio-Pharma Inc., a company involved in cannabinoid-derived drug discovery and development, announced that the company had been granted a Health Canada Drug Establishment License (DEL) to distribute REDUVO soft gel capsules in Canada. REDUVO is a synthetic tetrahydrocannabinol-based soft gel capsule indicated in severe nausea and vomiting associated with cancer chemotherapy.

In September 2020, Sandoz announced the launch of generic antiemetic medicine Fosaprepitant injection 150 mg in the U.S., enhancing hospital offerings and strategically expanding its injectables portfolio. Fosaprepitant is an antiemetic drug used in adults for the prevention of nausea and vomiting associated with certain chemotherapies.

In December 2020, Jupiter Wellness, Inc., a pharmaceutical company, signed a definitive agreement to merge with Next Frontier Pharmaceuticals, Inc., a drug developer and manufacturer of synthetic cannabinoid pharmaceuticals. Next Frontier Pharmaceuticals owns the only U.S. FDA approved CII Tetrahydrocannabinol (THC), a liquid cannabinoid, SYNDROS, used in adults to treat chemotherapy-induced nausea and vomiting.

In February, 2020, Camber Pharmaceuticals Inc., a fully integrated international pharmaceutical company, announced the launch of Dronabinol capsules to its portfolio of products. Dronbinol is used to treat nausea and vomiting caused by cancer chemotherapy.